Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients
P. Kuna, I. Vinkler, T. Overend, S. Snape, R. Tansley (Lodz, Poland; Nyiregyhaza, Hungary; Horsham, Saffron Walden, United Kingdom)
Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Session: Mechanisms and new treatments of COPD
Session type: Thematic Poster Session
Number: 2135
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Kuna, I. Vinkler, T. Overend, S. Snape, R. Tansley (Lodz, Poland; Nyiregyhaza, Hungary; Horsham, Saffron Walden, United Kingdom). Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Eur Respir J 2007; 30: Suppl. 51, 2135
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Safety and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
The efficacy and safety of long-acting muscarinic antagonist treatment for COPD Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma Year: 2019
Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007
The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study}, Source: Eur Respir J 2012; 40: 830-836 Year: 2012
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Efficacy and safety of AZD3199, an inhaled ultra long-acting β2 -agonist, in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Efficacy of nebulized arformoterol, a long-acting β2 -adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
ACCLaim/COPD II: efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist in COPD patients, a phase III study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Safety and pharmacokinetics of aclidinium bromide, a novel, long-acting muscarinic antagonist, in renally impaired subjects Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009